PH12014502239A1 - Use of ccr3-inhibitors - Google Patents
Use of ccr3-inhibitorsInfo
- Publication number
- PH12014502239A1 PH12014502239A1 PH12014502239A PH12014502239A PH12014502239A1 PH 12014502239 A1 PH12014502239 A1 PH 12014502239A1 PH 12014502239 A PH12014502239 A PH 12014502239A PH 12014502239 A PH12014502239 A PH 12014502239A PH 12014502239 A1 PH12014502239 A1 PH 12014502239A1
- Authority
- PH
- Philippines
- Prior art keywords
- eosinophilic
- alkyl
- macular degeneration
- related macular
- syndrome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Structure Of Transmissions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12162937 | 2012-04-03 | ||
| PCT/EP2013/056864 WO2013149986A1 (en) | 2012-04-03 | 2013-04-02 | Use of ccr3-inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12014502239A1 true PH12014502239A1 (en) | 2014-12-15 |
Family
ID=48040249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12014502239A PH12014502239A1 (en) | 2012-04-03 | 2014-10-03 | Use of ccr3-inhibitors |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US20130261153A1 (enExample) |
| EP (3) | EP3763369B1 (enExample) |
| JP (2) | JP2015512432A (enExample) |
| KR (5) | KR20140144200A (enExample) |
| CN (2) | CN104220073A (enExample) |
| AU (1) | AU2013245027B2 (enExample) |
| BR (1) | BR112014023795B1 (enExample) |
| CA (1) | CA2869269C (enExample) |
| CL (1) | CL2014002523A1 (enExample) |
| CY (1) | CY1123222T1 (enExample) |
| DK (1) | DK2833884T3 (enExample) |
| EA (1) | EA032263B1 (enExample) |
| ES (2) | ES2987267T3 (enExample) |
| HR (1) | HRP20201165T1 (enExample) |
| HU (1) | HUE051648T2 (enExample) |
| IL (1) | IL234262A (enExample) |
| IN (1) | IN2014DN06989A (enExample) |
| LT (1) | LT2833884T (enExample) |
| MX (1) | MX2014011786A (enExample) |
| NZ (1) | NZ628882A (enExample) |
| PH (1) | PH12014502239A1 (enExample) |
| PL (1) | PL2833884T3 (enExample) |
| PT (1) | PT2833884T (enExample) |
| RS (1) | RS60665B1 (enExample) |
| SI (1) | SI2833884T1 (enExample) |
| SM (1) | SMT202000499T1 (enExample) |
| WO (1) | WO2013149986A1 (enExample) |
| ZA (1) | ZA201406082B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US8680280B2 (en) | 2012-04-02 | 2014-03-25 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of CRR inhibitors |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| US11045284B2 (en) | 2016-11-24 | 2021-06-29 | Kirishima Seiko Co., Ltd. | Dental brace and method for attaching dental brace |
| BR112019020798A2 (pt) * | 2017-04-05 | 2020-04-28 | Alkahest Inc | métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3 |
| ES3046717T3 (en) * | 2017-04-05 | 2025-12-02 | Alkahest Inc | Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors |
| US20190111042A1 (en) * | 2017-10-13 | 2019-04-18 | Alkahest, Inc. | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR-Inhibitors |
| US11426399B2 (en) | 2018-05-15 | 2022-08-30 | Alkahest, Inc. | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase |
| EP3856195A4 (en) * | 2018-09-26 | 2022-06-22 | Alkahest, Inc. | METHODS AND COMPOSITIONS FOR TREATMENT OF AGING-RELATED DISORDERS USING CCR3 INHIBITORS |
| US20230312697A1 (en) | 2020-06-11 | 2023-10-05 | Alkahest Inc. | Methods of improving retina-associated disease outcome using ccr3-inhibitors |
| AU2022376563A1 (en) | 2021-11-01 | 2023-12-07 | Alkahest, Inc. | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339087B1 (en) * | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| BRPI0108923B8 (pt) * | 2000-03-03 | 2021-05-25 | Cambridge Antibody Tech Limited | elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina |
| US20020151064A1 (en) * | 2001-02-07 | 2002-10-17 | Children's Hospital Medical Center | Regulation of CCR3 expression |
| WO2006083390A2 (en) * | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxin-3 in eosinophilic esophagitis |
| US8008092B2 (en) * | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
| WO2010069979A1 (en) * | 2008-12-16 | 2010-06-24 | Nycomed Gmbh | Pyran derivatives as ccr3 modulators |
| EP2236520A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Stabilizing composition for immobilized biomolecules |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| US8778616B2 (en) * | 2009-05-26 | 2014-07-15 | University Of Kentucky Research Foundation | Method of using CCR3 binding agents to detect choroidal neovascularization |
| UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| WO2020115836A1 (ja) * | 2018-12-05 | 2020-06-11 | 東浜工業株式会社 | ブロワー装置 |
-
2013
- 2013-03-27 US US13/851,564 patent/US20130261153A1/en not_active Abandoned
- 2013-04-02 KR KR1020147027679A patent/KR20140144200A/ko not_active Ceased
- 2013-04-02 ES ES20174399T patent/ES2987267T3/es active Active
- 2013-04-02 AU AU2013245027A patent/AU2013245027B2/en active Active
- 2013-04-02 SM SM20200499T patent/SMT202000499T1/it unknown
- 2013-04-02 CN CN201380016333.7A patent/CN104220073A/zh active Pending
- 2013-04-02 EP EP20174399.4A patent/EP3763369B1/en active Active
- 2013-04-02 CA CA2869269A patent/CA2869269C/en active Active
- 2013-04-02 LT LTEP13713199.1T patent/LT2833884T/lt unknown
- 2013-04-02 BR BR112014023795-6A patent/BR112014023795B1/pt active IP Right Grant
- 2013-04-02 JP JP2015503847A patent/JP2015512432A/ja active Pending
- 2013-04-02 EA EA201401083A patent/EA032263B1/ru unknown
- 2013-04-02 CN CN201910406245.7A patent/CN110384699A/zh active Pending
- 2013-04-02 NZ NZ628882A patent/NZ628882A/en unknown
- 2013-04-02 ES ES13713199T patent/ES2811554T3/es active Active
- 2013-04-02 HR HRP20201165TT patent/HRP20201165T1/hr unknown
- 2013-04-02 PT PT137131991T patent/PT2833884T/pt unknown
- 2013-04-02 KR KR1020217015686A patent/KR20210063481A/ko not_active Ceased
- 2013-04-02 MX MX2014011786A patent/MX2014011786A/es unknown
- 2013-04-02 HU HUE13713199A patent/HUE051648T2/hu unknown
- 2013-04-02 EP EP24158785.6A patent/EP4389217A3/en active Pending
- 2013-04-02 PL PL13713199T patent/PL2833884T3/pl unknown
- 2013-04-02 WO PCT/EP2013/056864 patent/WO2013149986A1/en not_active Ceased
- 2013-04-02 KR KR1020227031439A patent/KR20220132012A/ko not_active Ceased
- 2013-04-02 KR KR1020257028220A patent/KR20250133980A/ko active Pending
- 2013-04-02 IN IN6989DEN2014 patent/IN2014DN06989A/en unknown
- 2013-04-02 SI SI201331753T patent/SI2833884T1/sl unknown
- 2013-04-02 EP EP13713199.1A patent/EP2833884B1/en active Active
- 2013-04-02 DK DK13713199.1T patent/DK2833884T3/da active
- 2013-04-02 KR KR1020207011392A patent/KR20200044988A/ko not_active Ceased
- 2013-04-02 RS RS20200868A patent/RS60665B1/sr unknown
-
2014
- 2014-08-19 ZA ZA2014/06082A patent/ZA201406082B/en unknown
- 2014-08-24 IL IL234262A patent/IL234262A/en active IP Right Grant
- 2014-09-24 CL CL2014002523A patent/CL2014002523A1/es unknown
- 2014-10-03 PH PH12014502239A patent/PH12014502239A1/en unknown
- 2014-12-15 US US14/570,298 patent/US20150099783A1/en not_active Abandoned
-
2015
- 2015-11-30 US US14/953,480 patent/US20160081998A1/en not_active Abandoned
-
2017
- 2017-07-25 US US15/658,918 patent/US20170319567A1/en not_active Abandoned
- 2017-12-22 JP JP2017246173A patent/JP2018080183A/ja not_active Withdrawn
-
2020
- 2020-07-23 CY CY20201100678T patent/CY1123222T1/el unknown
- 2020-08-19 US US16/997,772 patent/US20200375971A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502239A1 (en) | Use of ccr3-inhibitors | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| EA201590930A1 (ru) | Лекарственные формы руксолитиниба с замедленным высвобождением | |
| SA518400493B1 (ar) | مركبات كارفيلزوميب معالجة ببولي إيثيلين جليكول | |
| EA201391230A1 (ru) | Соединения и композиции в качестве ингибиторов trk | |
| JO3453B1 (ar) | مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1 | |
| EA201200176A1 (ru) | Производные оксазина и их применение для лечения неврологических нарушений | |
| SA515360007B1 (ar) | مركبات عطرية غير متجانسة كمثبطات بروتونز تيروسين كيناز ( btk) | |
| TR201816379T4 (tr) | DNA-PK inhibitörleri. | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
| EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
| EA201290952A1 (ru) | Химические соединения | |
| NZ703989A (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| EA201590358A1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
| MX2013007558A (es) | 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2). | |
| EA201490103A1 (ru) | Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1 | |
| EA201500182A1 (ru) | 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ | |
| MD20150075A2 (ro) | Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale | |
| GEP20156318B (en) | Heteroaryl derivatives as alpha7 nachr modulators | |
| PH12013500644A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| EA201591180A1 (ru) | Составы ингибитора lfa-1 | |
| EA201490721A1 (ru) | Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы | |
| MX348024B (es) | Compuestos de adamantilo. | |
| EA201501187A1 (ru) | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |